Φορτώνει......
Targeting CD38 enhances the antileukemic activity of ibrutinib in chronic lymphocytic leukemia (CLL).
PURPOSE: CD38 has emerged as a high-impact therapeutic target in multiple myeloma, with the approval of daratumumab (anti-CD38 monoclonal antibody). The clinical importance of CD38 in chronic lymphocytic leukemia (CLL) patients has been known for over two decades, though it’s relevance as a therapeu...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Clin Cancer Res |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , , , , , , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6744942/ https://ncbi.nlm.nih.gov/pubmed/30940652 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-3412 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|